Professional Seasonal Analysis for Trading

Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)

Seasonality Analysis

Stocks 5 Years Analyzed

Day One Biopharmaceuticals, Inc. - Common Stock Annual Seasonality Statistics

31.83%
Avg Annual Return
50.0%
Avg Monthly Win Rate
8/12
Positive Months
5
Years Analyzed

Day One Biopharmaceuticals, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January 3.80%
60%
Moderate
February -9.57%
20%
Very Weak
March 8.78%
20%
Weak
April -3.31%
60%
Weak
May WORST -16.30%
20%
Very Weak
June BEST 32.90%
60%
Moderate
July 1.18%
80%
Moderate
August 14.19%
80%
Very Strong
September -8.88%
20%
Very Weak
October 3.31%
60%
Moderate
November 1.57%
40%
Weak
December 4.15%
80%
Very Strong

Day One Biopharmaceuticals, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
99.81
Historical Avg Position
24.67
Deviation
+75.13
Performance
Significantly Above Average

Day One Biopharmaceuticals, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for DAWN with overlay patterns, custom date ranges, and more.

Create Free Account

Day One Biopharmaceuticals, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Day One Biopharmaceuticals, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for DAWN across multiple timeframes.

Create Free Account

About Day One Biopharmaceuticals, Inc. - Common Stock (DAWN) Seasonality

Day One Biopharmaceuticals, Inc. - Common Stock (DAWN) has been analyzed using 5 years of historical data to identify seasonal patterns. Classified under Stocks, Day One Biopharmaceuticals, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Day One Biopharmaceuticals, Inc. - Common Stock is historically June, with an average return of 32.90% and a win rate of 60%. Conversely, May tends to be the weakest month, averaging -16.30% return.

Looking at the full calendar year, Day One Biopharmaceuticals, Inc. - Common Stock has an average annual return of 31.83% with an overall monthly win rate of 50.0%. Out of 12 months, 8 typically show positive average returns.

The seasonal pattern for Day One Biopharmaceuticals, Inc. - Common Stock has a consistency score of 47 (Poor), based on 6 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Day One Biopharmaceuticals, Inc. - Common Stock Seasonality FAQ

What is the best month to buy Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)?

Historically, June has been the best month for Day One Biopharmaceuticals, Inc. - Common Stock, with an average return of 32.90% and a win rate of 60%. However, past performance does not guarantee future results.

What is the worst month for Day One Biopharmaceuticals, Inc. - Common Stock (DAWN)?

Based on historical data, May has been the weakest month for Day One Biopharmaceuticals, Inc. - Common Stock, with an average return of -16.30%. This is a historical observation and does not guarantee future results.

How reliable is DAWN seasonality data?

The seasonality analysis for Day One Biopharmaceuticals, Inc. - Common Stock is based on 5 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Day One Biopharmaceuticals, Inc. - Common Stock seasonality in my trading?

Use Day One Biopharmaceuticals, Inc. - Common Stock (DAWN) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.